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One of the important posttranslational protein modifications is histone acetylation or 
deacetylation. Acetylation is catalyzed by the dedicated histone acetyltransferases and 
has been generally considered to be associated with transcription activation, while 
deacetylation is catalyzed by histone deacetylases (HDACs). One of the classes of 
HDACs called sirtuins are NAD
+
-dependent deacetylases. There are seven sirtuins in 
mammals from Sirt1 – Sirt7. In this work, we study Sirt6, one of the sirtuins reported 
to have a weak deacetylase activity in vitro. However, Sirt6 has been involved in 
various important biological functions like life span expansion, genomic stability, 
transcriptional regulation, and metabolism. At the biochemical level, Sirt6 
deacetylation has been attributed to most of these biological functions. 
We found that human sirtuin Sirt6 can remove longer chain fattyacyl groups, 
such as myristoyl group, on the lysine residue much more efficiently than acetyl 
group. It is shown that this novel activity of Sirt6 allows it to accommodate more 
substrates other than H3K9. The catalytic efficiency for this new defattyacylase 
activity was found to be comparable to sirtuins with robust deacetylase activity. 
Further, the physiological relevance of this activity shows that Sirt6 promotes the 
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1.1 Posttranslational Modification and its Immediate Biological Implications 
The global set of proteins produced by an organism is called the proteome. It 
results firstly from the direct translation of the genome, secondly from the diversification 
at the mRNA level (either through alternative splicing at the mRNA level or by using 
alternative promoter sequence), and thirdly by the diversification of the translated protein 
through covalent modifications. The chemical modification of the protein either by the 
covalent addition of small molecules to the amino acid side chain or the hydrolytic 
cleavage of peptide bond(s) of the protein is broadly termed as posttranslational 
modification (PTM). Some of the direct consequences of PTMs result in the following 
functional changes in proteins (1): 
1) activation/deactivation of the protein catalytic activity,  
2) change in the localization of proteins, and 
3) change in protein-protein interactions. 
The examples of PTMs and their biological implications are numerous. 
Ser/Thr/Tyr phosphorylation is known to be involved in inducing the signal transduction 
pathways either by switching its catalytic activity or by producing binding sites for the 
partners (2). Lysine methylation and acetylation on histones regulate gene transcription 
(3). The fattyacylation of proteins, namely N-myristoylation and S-palmitoylation, are 
responsible for membrane targeting of proteins (4). Protein polyubiquitylation helps in 
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protein degradation, endocytosis, and cell signaling (5, 6). These are just a few examples 
that show that PTMs are involved in many important biological processes. 
 
1.2 Lysine Acetylation – Histone Acetyltransferases (HATs) 
Lysine acetylation is an important PTM that is involved in regulating the 
transcription of genes associated with histones. The acetylation of histones is catalyzed by 
a family of proteins called histone acetyltransferases (HATs) and is considered to be 
associated with transcriptional activation. In addition to histones, lysine acetylation has 
been reported to occur in several other proteins (7-10). Recently, several novel acyl lysine 
modifications have been discovered. A few examples of such modifications include 
propionylation, butyrylation, crotonoylation, succinylation, malonylation, and 
myristoylation (11). 
 
1.3 Lysine Deacetylation – Histone Deacetylases (HDACs) 
The deacetylation of histones is catalyzed by another family of proteins called 
histone deacetylases (HDACs) and is associated with transcriptional silencing (12). 
HDACs keep these lysine side chains hypoacetylated, thereby condensing the 
chromosomes and keeping the transcriptional machinery shut down (1, 13). 
There are eighteen HDACs in mammals which are divided into four classes, 
namely class I-IV, based on their sequence homology to yeast Sir2. Classes I, II, and IV 
are commonly known as classical HDACs and comprise eleven members. Class III 
HDACs are called “sirtuins” and there are seven sirtuins in mammals. Classical HDACs 
differ from sirtuins in their catalytic mechanism for the deacetylation of histones. The 
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HDACs make use of Zn
+2
 ion in the catalytic pocket and act as metal dependent amide- 
hydrolases, whereas sirtuins use nicotinamide adenine dinucleotide (NAD
+
) cofactor as a 
co-substrate to hydrolyze the acetyl group from the side chain lysine of histones – the  
detailed mechanism of the same is discussed in the next section. 
 
1.3.1 Sirtuins 
The founding member of the sirtuin family is the yeast Sir2 (Silent Mating Type 
Information Regulator), which has been known to be a silencing factor. The histone 
deacetylase activity of the yeast Sir2 has been attributed to gene silencing. Also, it has 
been shown to be responsible for the life span expansion of yeast during the caloric 
restriction (14-16). The simple phylogenetic classification (17) of sirtuins in different 
species is shown in Fig. 1.1.  
 
 
Fig. 1.1 Phylogenetic classification of sirtuins in bacteria, archaea, and eukaryotes: the 
white and black letterings of figure signify the associated deacetylation and ADP-ribosyl 
transferase activity. (Figure taken from Int. J. Dev. Biol. 53, 303-322 (2009)). 
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The functions of sirtuins are conserved from archaea to eukaryotes, so these 
phylogenetic trees are helpful in inferring a new activity for sirtuins from one species to a 
different species.  
Mammalian sirtuins, Sirt1-7, based on their sequence similarity have been 
grouped roughly in four classes: Sirt1, Sirt2, and Sirt3 form class I, Sirt4 is class II, Sirt5 
is class III, and Sirt6 and Sirt7 are class IV sirtuins. Sirtuins have been reported earlier to 
be found in different sub-cellular localizations. Sirt1, Sirt6, and Sirt7 are found in the 
nucleus, Sirt2 is found in the cytosol, and Sirt3, Sirt4, and Sirt5 are found in the 
mitochondria. However, there are reports including some work from our research group 
indicating that localizations might be different from that stated above (18). All 
mammalian sirtuins have been thought to be NAD
+
-dependent histone deacetylases. The 
most accepted mechanism of deacetylation is shown in Fig. 1.2. The mechanism has been 
extensively studied (19-26). It can be described as a two step process, which proceeds 
firstly with the acetyl oxygen attacking the anomeric carbon of the sugar back bone, 
releasing nicotinamide as a by-product and forming an α-1´-O-alkylimidate intermediate. 
The 2´-OH then attacks the intermediate, followed by hydrolysis to give the 2´-O-acetyl-
ADP-ribose (O-Ac-ADPR), which can isomerize to form 3´-O-Ac-ADPR non-
enzymatically. A conserved histidine residue has been shown to be involved in the 
catalysis. 
Sirtuins have been reported to be involved in a number of biological functions. 
These functions include the regulation of life span, transcription, apoptosis, genome 
stability, and metabolism (27-29). 
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Fig. 1.2 Sirtuin catalyzed NAD-dependent deacetylation reaction and the most accepted 
mechanism.  
 
1.3.2 Crystal Structure of Sirtuins  
The crystal structure of different sirtuins with various ligands has been reported 
(30). Sirtuins typically contain Zn
+2 
coordinated by four conserved cysteine residues. The 
Zn
+2 
ion is necessary for keeping the structure intact. There are two domains in the crystal 
structure: a smaller Zn
+2 
binding domain and the larger domain containing a Rossmann 
fold for binding NAD
+ 
(Fig. 1.3). The N and C termini vary in the sequence whereas the 
core catalytic domain is more or less conserved in sirtuins. The large and the small 
domains are connected through loops in such a way that a cleft is formed, which is where 
the substrate and NAD
+
 bind the protein from the opposite directions. 
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Fig. 1.3 Overall crystal structure of Sirt6 with Myr-H3K9 peptide (in green) and ADPR 





1.4 Motivation and Prior Work on Sirtuin 6 
At the biochemical level, only a few sirtuins have robust deacetylation activity. 
For instance, Sirt1, Sirt2, and Sirt3 have been reported to exhibit robust deacetylation 
activity. Sirt4 has no deacetylation activity (31, 32). On the other hand, Sirt5 (33, 34), 
Sirt6 (35), and Sirt7 (32) have been known to have very weak deacetylation activity. The 
gap between important biological activities and the lack of robust deacetylation activity 
prompted us to think that the sirtuins with the weak deacetylase activity might remove 
other physiologically relevant modification on the lysine residue. 
  7 
Du et al. demonstrated that the above hypothesis is indeed true in human Sirt5 
(36). They showed that Sirt5 removes the malonyl and succinyl modifications on lysine 
residues much more efficiently than the deacetylation activity and that protein 
succinylation and malonylation occur in cells. Based on the information from the crystal 
structure of Sirt5 with thioacetyl peptide, they predicted that if the acetyl group is 
replaced with an acyl group bearing a negatively charged carboxylate ion, the acyl 
peptide would bind Sirt5 better than the acetyl peptide. Therefore, such modifications 
might be better substrates for Sirt5. Du et al. further tested the malonyl and succinyl 
modifications on various peptides as the physiologically relevant substrates for Sirt5. This 
was the first evidence that a sirtuin could preferentially remove an acyl modification other 
than the known acetyl group more efficiently. This work made us think that Sirt6, which 
was reported to have a weak deacetylase activity, could also prefer to hydrolyze other 
acyl modifications. In this thesis, we have proved this hypothesis by showing that Sirt6 
prefers to hydrolyze medium and long chain fattyacyl groups. 
 
1.4.1 Sirt6 Prior Work 
A brief mention of prior work on Sirt6 is important to establish the necessity for 
exploring the new activity of Sirt6, which has been reported to be a nuclear protein (32). 
Sirt6 is known to possess two weak biochemical activities namely ADP-ribosyltransferase 
activity and deacetylation activity. Although weak, both activities have important 
biological functions as described below. 
Sirt6 has been reported to possess mono-ADP-ribosyltransferase activity. At the 
biochemical level, this happens when sirtuins transfer ADP-ribose moiety of NAD
+
 to 
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other proteins. Earlier, Sirt6 was found to ADP-ribosylate itself. However this activity 
was thought to be weak. (37). Du et al. showed by using the NAD analogues that this 
activity might be too weak to be physiologically relevant (38). Recently, it has been 
demonstrated that during oxidative stress, Sirt6 ADP-ribosylates PARP-1 and promotes 
DNA repair (39). This activity has also been attributed to the role of Sirt6 in inducing 
massive apoptosis in the cancerous cells selectively (40). 
Sirt6 has been reported to have sequence specific weak deacetylase activity on 
H3K9 and H3K56 histone substrates (35, 41, 42). Most of the biological functions of 
Sirt6 have been associated to this weak deacetylase activity. However, no measurement of 
its enzymatic efficiency (i.e. kcat, Km) has been reported so far. The various biological 
functions have been elaborated below in which deacetylation activity of Sirt6 has been 
thought to be involved. 
 
Aging   
It has been shown that Sirt6 over expression increases the life span of the male 
mice. Sirt6 knock out (KO) mice were reported to show the phenotype of aging (43). On 
cellular levels, studies have shown that Sirt6 knock down (KD) cells show increased 
genomic instability, susceptibility towards ionizing radiation, phenotype of defective base 
excision repair (BER), and DNA double-strand break (DSB) repair. 
 
Metabolism  
Recent work by Mostoslavasky et al. (44) demonstrated that Sirt6 is a corepressor 
of hypoxia-inducible factor 1-alpha (Hif1α) gene. The overexpression of Sirt6 was shown 
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to down regulate the various glycolytic genes. Sirt6 deficient mice were shown to suffer 
from acute hypoglycemia. All these results indicate that Sirt6 is an important player in 
glucose metabolism. In another finding, Sirt6 has also been shown to promote fat 
utilization by fatty acid oxidation in wildtype mice. It has been shown that Sirt1, 
FOXO3a, and NRF1 form a complex and positively regulate Sirt6 gene expression, which 
in turn negatively regulates glycolysis, triglyceride synthesis, and fat metabolism. Sirt6 
has been shown to deacetylate H3K9 in the promoter region of the genes involved in 
glycolysis, triglyceride synthesis and fat metabolism (45). 
 
Genome Stability and Sirtuins 
Sirt6 has been reported to be important in maintaining telomere integrity by deacet 
lating H3K9 and H3K56 histone sequences (35). Telomeres are sequences at the end of 
chromosomes and provide protection from aberrant DNA repair, fusion, and degradation 
of the chromosome ends. Sirt6 depletion leads to abnormal telomere metabolism. 
Genomic stability is also maintained by Sirt6 mediated DNA repair. It is important at the 
DNA DSB repair sites because it induces structural changes in chromatin at these DSB 
sites, which is essential for the efficient association of DSB repair proteins (46). DNA 
dependent protein kinase or DNA-PK is one such example of DSB repair protein. DNA-
PK is a non-homologous end joining (NHEJ) holoenzyme, which in turn repairs DSBs 
using an NHEJ mechanism. Sirt6 has also been reported to promote DSB repair through 
homologous recombination which happens in two steps firstly by activating PARP-1, and 
secondly by deacetylating and thereby activating the end resection protein called CtIP.  
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Inflammation Response 
NF-κB has been known to be a key transcription factor in aging, proliferation, and 
for the control of inflammation response genes (47). It was recently reported that Sirt6 
interacts with NF-κB physically and is recruited to the promoters of several NF-κB target 
genes by deacetylating these promoters at the H3K9 position, and thereby decreasing the 
NF-κB signaling (48). 
 
1.5 Connection between TNFα and Sirt6   
The involvement of Sirt6  in regulating the synthesis of the tumor necrosis factor α 
(TNFα) in a NAD+ dependent manner has been demonstrated by two research groups (49, 
50).  TNFα is a type II membrane protein that is known to be involved in systemic 
inflammation. It is central to many signaling pathways like NF-κB and mitogen-activated 
protein kinase (MAPK) pathway. TNFα has been shown to be myristoylated at K19 and 
K20 residues (51, 52). While exploring the new enzymatic activity for Sirt6 (as described 
in Section 1.4), we discovered that Sirt6 possesses a novel defattyacylase activity. That is, 
it prefers to remove longer chain fattyacyl group modification on histone peptides. We 
made use of the above information and demonstrated that Sirt6 might affect the TNFα 
secretion by defattyacylating it. The details of our approach are described in the next 
section. 
 
1.6 My Dissertation Statement 
My dissertation work investigates the class IV sirtuin, Sirt6, which has been 
reported to be important for DNA repair, transcriptional regulation of genes involved in 
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metabolism and inflammation, genome stability, and for life span expansion. Almost all 
the biological functions of Sirt6 have been attributed to its weak and site specific histone 
deacetylase activity. My goal was to look for alternate acyl lysine modifications which 
might be removed by Sirt6. I showed that Sirt6 hydrolyzes longer chain acyl 
modifications much more efficiently than the short acetyl modification on lysine residues 
of the histone peptide. Therefore, defattyacylation is a novel Sirt6 activity. 
In Chapter 2, I present biochemical and enzymology data establishing a novel 
activity for Sirt6 which is much more efficient than the previously reported weak 
deacetylase activity, which was thought to be responsible for its myriad biological 
functions. Using various biochemical techniques such as HPLC coupled with mass 
spectroscopy, I demonstrated that Sirt6 shows preference for removing longer chain acyl 
modifications in comparison to other physiologically relevant modifications such as 
biotin, hydroxyl methyl glutaryl (HMG) succinyl, lipoyl, acetyl, ubiquitinyl, and SUMOyl 
(small peptide sequences from ubiquitin and SUMO peptide) on Lys9 of the H3K9 
peptide. I further determined that Sirt6 removes myristoyl group from the H3K9 peptide 
approximately 300 fold better than its acetyl counterpart.  
Also, I used HPLC based techniques to show that this more efficient activity also 
allows Sirt6 to utilize substrates other than H3K9acetyl peptide. Using autoradiography, 
HPLC, and MALDI-TOF mass spectroscopy, I showed that the reaction mechanism for 
this novel Sirt6 “demyristoylase” activity is the same as that which has been established 
for deacetylase activity. The preference for longer chain fattyacyl group has been 
demonstrated using the crystal structure of Sirt6 with H3K9myr peptide and ADP-ribose. 
This chapter also includes some of my efforts towards determining whether or not 
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histones have these long chain fattyacyl modifications. It also includes a brief 
acknowledgement to the work of my colleague Hong Jiang in establishing the 
physiological relevance for demyristoylase activity of Sirt6. In summary, he showed that 
Sirt6 promotes the secretion of TNFα by removing the fattyacyl modification on 
Lys19/20 of TNFα. To corroborate this at the biochemical level, using HPLC based in 
vitro activity assay, I showed that Sirt6 could indeed remove myristoyl groups from 
Lys19 and Lys20 of a synthetic TNFα peptide. Also, I obtained kinetic data using HPLC 
based assays to show that the demyristoylation of TNFα K19myr and TNFα K20myr 
peptides was as efficient as deacetylase activity of sirtuins Sirt1-3, which exhibit robust 
deacetylation activity. Some of these results are also available in reference (53). 
In Chapter 3, I present possible extensions and some of the incomplete work on 
Sirt6. Firstly, my goal was to clone and express the Sirt6 mutant that would abrogate the 
defattyacylation activity. We made use of the crystal structure to identify four such 
residues, Leu9, Val115, Phe82, and Phe86 that were in close interaction with the 
hydrophobic myristoyl chain. I was able to mutate and express three of them, Leu9, 
Val115, and Phe82, to more hydrophilic arginine residue. Further studies need to be done 
for the activity of these mutated proteins with TNFα myristoyl peptides and H3K9 
myristoyl peptides to confirm which one abrogates the defattyacylation activity. The 
chapter also includes some proposed experiments to explore how the recently reported 
ADP-ribosyl transferase activity of Sirt6 might affect our defattyacylase activity.  
Chapter 4 provides important concluding remarks, briefs about the significance of 
this work, and presents a few future directions that we can pursue based on this work. 
 
  13 
REFERENCES 
 
1. Walsh, C. T., Posttranslational Modification of Proteins: Expanding Nature‟s 
Inventory. Roberts and Company Publishers, Englewood, Colorado (2005). 
2. Johnson, L. N. and Lewis, R. J., Structural Basis for Control by Phosphorylation.     
Chem. Rev. 101, 2209-2242 (2001). 
3. Jenuwein, T. and Allis, C. D., Translating the Histone Code. Science 293, 1074- 
1080 (2001). 
4. Resh M. D., Fattyacylation of Protein: New Insights into Membrane Targeting   of   
Myristoylated and Palmitoylated Proteins. Biochem. Biophys. Acta 1451, 1-16 
(1999). 
5. Kerscher, O., Felberbaum, R. and Hochstrasser, M., Modification of Proteins by 
Ubiquitin and Ubiquitin-Like Proteins. Annu. Rev. Cell Dev. Biol. 22, 159-180 
(2006). 
6. Mukhopadhyay, D. and Riezman, H., Proteasome-Independent Functions of 
Ubiquitin in Endocytosis and Signaling. Science 315, 201-205 (2007). 
7. Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang, T. et al., Regulation of 
Cellular Metabolism by Protein Lysine Acetylation. Science 327, 1000-1004 
(2010). 
8. Wang, Q., Zhang, Y., Yang, C., Xiong, H., Lin, Y., Yao, J. et al., Acetylation of 
Metabolic Enzymes Coordinates Carbon Source Utilization and Metabolic Flux. 
Science 327, 1004-1007 (2010). 
  14 
9. Schwer, B., Bunkenborg, J., Verdin, R. O., Andersen, J. S. and Verdin, E., 
Reversible Lysine Acetylation Controls the Activity of the Mitochondrial Enzyme 
Acetyl-CoA Synthetase 2. Proc. Natl. Acad. Sci. U. S. A. 103, 10224-10229 
(2006). 
10. Starai, V. J., Celic, I., Cole, R. N., Boeke, J. D. and Escalante-Semerena, J. C., 
Sir2-Dependent Activation of Acetyl-CoA Synthetase by Deacetylation of Active 
Lysine. Science 298, 2390-2392 (2002). 
11. Su, X., He B., and Lin, H., Protein Lysine Acylation and Cysteine Succination by 
Intermediates of Energy Metabolism. ACS Chem. Bio. 7(6), 947-60, June 15 
(2012). 
12. Shahbazian, M. D. and Grunstein, M., Functions of Site-Specific Histone 
Acetylation and Deacetylation. Annu. Rev. Biochem. 76, 75-100 (2007). 
13. Verdin, E., Dequiedt, F., and Kasler, H. G., Class II Histones Deacetylases: 
Versatile Regulators. Trends Genet. 19, 286-294 (2003). 
14. Kaeberlein, M., McVey, M., and Guarente, L., The SIR2/3/4 Complex and SIR2 
Alone Promote Longevity in Saccharomyces Cerevisiae by Two Different 
Mechanisms. Genes Dev. 13, 2570-2580 (1999). 
15. Lin, S. J., Defossez, P. A., and Guarente, L., Requirement of NAD and SIR2 for 
Life-Span Extension by Calorie Restriction in Saccharomyces Cerevisiae. Science 
289, 2126-2128 (2000). 
16. Imai, S.-I., Armstrong, C. M., Kaeberlein, M. and Guarente, L., Transcriptional     
Silencing and Longevity Protein Sir2 is an NAD-Dependent Histone Deacetylase. 
Nature 403, 795-800 (2000). 
  15 
17. Vaquero, A., The Conserved Role of Sirtuins in Chromatin Regulation. Int. J. Dev. 
Biol. 53, 303-322 (2009). 
18.  Schber, M. B., Vaquero, A., and Reinberg, D., SirT3 is a Nuclear NAD-
Dependent Histone Deacetylase that Translocates to the Mitochondria upon 
Cellular Stress. Genes Dev. 21, 920-928 (2007). 
19. Tanner, K. G., Landry, J., Sternglanz, R. and Denu, J. M., Silent Information 
Regulator 2 Family of NAD-Dependent Histone/Protein Deacetylases Generates a 
Unique Product, 1-O-Acetyl-ADP-Ribose. Proc. Natl. Acad. Sci. U. S. A. 97, 
14178-14182 (2000). 
20. Tanny, J. C. and Moazed, D., Coupling of Histone Deacetylation to NAD 
Breakdown by the Yeast Silencing Protein Sir2: Evidence for Acetyl Transfer 
from Substrate to an NAD Breakdown Product. Proc. Natl. Acad. Sci. U. S. A. 98, 
415-420 (2001). 
21. Sauve, A. A., Celic, I., Avalos, J., Deng, H., Boeke, J. D., and Schramm, V. L., 
Chemistry of Gene Silencing: The Mechanism of NAD
+
-Dependent Deacetylation 
Reactions. Biochemistry 40, 15456-15463 (2001). 
22. Jackson, M. D. and Denu, J. M., Structural Identification of 2´- and 3´-O-Acetyl-
ADP-Ribose as Novel Metabolites Derived from the Sir2 Family of Beta-NAD
+
-
Dependent Histone/Protein Deacetylases. J. Biol. Chem. 277, 18535-18544 
(2002). 
23. Jackson, M. D., Schmidt, M. T., Oppenheimer, N. J., and Denu, J. M., Mechanism 
of Nicotinamide Inhibition and Transglycosidation by Sir2 Histone/Protein 
Deacetylases. J. Biol. Chem. 278, 50985-50998 (2003). 
  16 
24. Smith, B. C. and Denu, J. M., Sir2 Protein Deacetylases: Evidence for Chemical 
Intermediates and Functions of a Conserved Histidine. Biochemistry 45, 272-282 
(2006). 
25. Smith, B. C. and Denu, J. M., Sir2 Deacetylases Exhibit Nucleophilic 
Participation of Acetyl-lysine in NAD
+
 Cleavage. J. Am. Chem. Soc. 129, 5802-
5803 (2007). 
26. Sauve, A. A. and Schramm, V. L., Sir2 Regulation by Nicotinamide Results from 
Switching between Base-Exchange and Deacetylation Chemistry. Biochemistry 
42, 9249-9256 (2003). 
27. Carlos, S., Satterstrom, F. K., Haigas, M., and Mostoslavasky, R., From Sirtuin 
Biology to Human Diseases: An Update. J. Bio. Chem. vol. 287, no. 51, 42444-
42452 (2012). 
28. Michan, S. and Sinclair, D., Sirtuins in Mammals: Insights into Their Biological      
Function. Biochem. J. 404, 1-13 (2007). 
29. Houtkooper, R. H., Pirinen, E., and Auwerx, J., Sirtuins as Regulators of 
Metabolism and Health Span., Nat. Rev. Mol. Cell Biol. 13, 225-238 (2012). 
30.  Yuan, H. and Marmorstein, R., Structural Basis for Sirtuin Activity and 
Inhibition. J. Bio. Chem. 287, 42428-42435 (2012). 
31. Haigis, M. C., Mostoslavsky, R., Haigis, K. M., Fahie, K., Christodoulou, D. C., 
Murphy, A. J. et al., SIRT4 Inhibits Glutamate Dehydrogenase and Opposes the 
Effects of Calorie Restriction in Pancreatic β Cells. Cell 126, 941-954 (2006). 
  17 
32. Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C., and Horikawa, I., 
Evolutionarily Conserved and Non-Conserved Cellular Localizations and 
Functions of Human SIRT Proteins. Mol. Biol. Cell 16, 4623-4635 (2005). 
33. Schuetz, A., Min, J., Antoshenko, T., Wang, C.-L., Allali-Hassani, A., Dong, A. et 
al., Structural Basis of Inhibition of the Human NAD
+
-Dependent Deacetylase 
SIRT5 by Suramin. Structure 15, 377-389 (2007). 
34. Schlicker, C., Gertz, M., Papatheodorou, P., Kachholz, B., Becker, C. F. W., and 
Steegborn, C., Substrates and Regulation Mechanisms for the Human 
Mitochondrial Sirtuins SirT3 and SirT5. J. Mol. Biol. 382, 790-801 (2008). 
35. Michishita, E., McCord, R. A., Berber, E., Kioi, M., Padilla-Nash, H., Damian, M. 
et al., SIRT6 is a Histone H3 Lysine 9 Deacetylase that Modulates Telomeric 
Chromatin. Nature 452, 492-496 (2008). 
36. Du, J., Zhou, Y., Su, X., Yu, J. J., Khan, S., Jiang, H., Kim, J., Woo, J., Kim, J. 
H., Choi, B. H., He, B., Chen, W., Zhang, S., Cerione, R. A., Auwerx, J., Hao, Q., 
and Lin, H., SirT5 is a NAD-Dependent Protein Lysine Demalonylase and 
Desuccinylase. Science 334, 806–809 (2011). 
37. Liszt, G., Ford, E., Kurtev, M., and Guarente, L., Mouse Sir2 Homolog SIRT6 is a 
Nuclear ADP-Ribosyltransferase. J. Biol. Chem. 280, 21313-21320 (2005). 
38. Du, J., Jiang, H., and Lin, H., Investigating the ADP-Ribosyltransferase Activity 
of Sirtuins with NAD Analogs and 
32
P-NAD. Biochemistry 48, 2878-2890 (2009). 
39. Mao Z, Hine C., Tian X., Van Meter M., Au M., Vaidya A., Seluanoy A., and    
Gorbunova V., SIRT6 Promotes DNA Repair under Stress by Activating PARP-1.   
Science 17, 332 (6036):1443-6, June (2011). 
  18 
40. Van, M. M., Mao, Z., Gorbunova, V., and Seluanov, A., SIRT6 Overexpression 
Induces Massive Apoptosis in Cancer Cells But Not in Normal Cells. Cell Cycle, 
10(18): 3153-8 (2011). 
41. Yang, B., Zwaans, B. M. M., Eckersdorff, M., and Lombard, D. B., The Sirtuin 
SIRT6 Deacetylates H3 K56Ac in vivo to Promote Genomic Stability. Cell Cycle 
8, 2662-2663 (2009). 
42. Michishita, E., McCord, R. A., Boxer, L. D., Barber, M. F., Hong, T., Gozani, O. 
et al., Cell Cycle-Dependent Deacetylation of Telomeric Histone H3 Lysine K56 
by Human SIRT6. Cell Cycle 8, 2664-2666 (2009). 
43. Kanfi, Y., Naiman, S., Amir, G., Peshti, V., Zinman, G., Nahum, L., Bar-     
Joseph, Z., and Cohen, H. Y., The Sirtuin SIRT6 Regulates Lifespan in Male 
Mice. Nature 483, 218-221 (2012) 
44. Zhong, L., D‟Urso, A., Toiber, D., Sebastian, C., Henry, R. E., Vadysirisack, D. 
D., Guimaraes, A., Marinelli, B., Wikstrom, J. D., Nir, T., Clish, C. B., 
Vaitheesvaran, B., Iliopoulos, O., Kurland, I., Dor, Y., Weissleder, R., Shirihai, O. 
S., Ellisen, L. W., Espinosa, J. M., and Mostoslavsky, R., The Histone 
Deacetylase Sirt6 Regulates Glucose Homeostasis via Hif1 α. Cell 140, 280-293 
(2010).  
45. Kim, H. S., Xiao, C., Wang, R. H., Lahusen, T., Xu, X., Vassilopoulos, A., 
Vazquez-Ortiz, G., Jeong, W. I., Park, O., Ki, S. H., Gao, B., and Deng, C. X., 
Hepatic-Specific Disruption of SIRT6 in Mice Results in Fatty Liver Formation 
due to Enhanced Glycolysis and Triglyceride Synthesis. Cell Metab. 12, 224-23 
(2010). 
  19 
46. McCord, R. A., et al., SIRT6 Stabilizes DNA-Dependent Protein Kinase at 
Chromatin for DNA Double-Strand Break Repair. Aging. 1, 109-121 (2009). 
47. Hayden, M. S., and Ghosh, S., Shared Principles in NF-kappaB Signaling. Cell 
132 (3), 344-62, Feb. 8 (2008). 
48. Kawahara, T. L., et al., SIRT6 Links Histone H3 Lysine 9 Deacetylation to NF-
kappaB-Dependent Gene Expression and Organismal Life Span. Cell 136, 62-74 
(2009) 
49. Bruzzone, S., Fruscione, F., Morando, S., Ferrando, T., Poggi, A., Garuti, A. et 
al., Catastrophic NAD Depletion in Activated T Lymphocytes through Nampt 
Inhibition Reduces Demyelination and Disability in EAE. PLoS ONE 4, e7897 
(2009). 
50. Van Gool, F., Galli, M., Gueydan, C., Kruys, V., Prevot, P.-P., Bedalov, A. et al., 
Intracellular NAD Levels Regulate Tumor Necrosis Factor Protein Synthesis in a 
Sirtuin-Dependent Manner. Nat. Med. 15, 206-210 (2009). 
51. Stevenson, F. T., Bursten, S. L., Locksley, R. M., and Lovett, D. H., Myristyl 
Acylation of the Tumor Necrosis Factor Alpha Precursor on Specific Lysine 
Residues. J. Exp. Med. 176, 1053-1062, (1992). 
52. Stevenson, F. T., Bursten, S. L., Fanton, C., Locksley, R. M., and Lovett, D. H.,  
The 31-kDa Precursor of Interleukin 1 Alpha is Myristoylated on Specific Lysines 
within the 16-kDa N Terminal Propiece. Proc. Natl. Acad. Sci. U. S. A. 90, 7245-
7249 (1993).  
53. Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., Kim, R., 
Mostoslavasky, R., Hang, H. C., Hao, Q., and Lin, H., Sirt6 Regulates TNFα via 
  20 























  21 
CHAPTER 2 
Sirt6 Regulates TNF-Secretion via Hydrolysis of Long Chain Fattyacyl Lysine 
 
2.1 Abstract 
The Sir2 family of enzymes (sirtuins) is known as nicotinamide adenine 
dinucleotide (NAD)-dependent deacetylases. However, four of the seven mammalian 
sirtuins including Sirt5 and Sirt6 have very weak or no deacetylase activity in vitro. 
Recently, it has been shown that Sirt5 possesses robust lysine desuccinylase and 
demalonylase activities in vitro. In this work, I show that human Sirt6 can efficiently 
remove long chain fattyacyl groups such as myristoyl from lysine residues in histone 
peptides. This novel activity further supports the statement that sirtuins are “NAD-
dependent deacylases” rather than commonly called NAD-dependent deacetylases. The 
crystal structure of Sirt6 discloses a large hydrophobic pocket that can accommodate long 
chain fattyacyl groups. Further, it has been demonstrated that Sirt6 could regulate TNFα 




Sirtuins are ancient family of proteins that are present in all life forms and exhibit 
a conserved structure and catalytic activity from bacteria to mammals. The first 
discovered member called as Sir2 (Silent mating type Information Regulator factor 2) in 
yeast, was identified as gene for silencing chromatin by working at the biochemical level 
as a histone deacetylase (1). The catalytic activity of the sirtuin family of proteins has 
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been attributed to their NAD
+
 cofactor dependent histone deacetylase activities (2, 3). 
Seven sirtuins, namely Sirt1 to Sirt7, found in mammals have been shown to be involved 
in various biological functions such as regulation of life span (4-8), genome stability (9), 
transcription (10-13), and metabolism (14-18). 
Four of the seven mammalian sirtuins including Sirt5 and Sirt6 have been reported 
to have very weak or no detectable deacetylase activity (19-22). Using the enzymology 
data and crystal structure, Du et al. recently showed that Sirt5 hydrolyzes malonyl and 
succinyl peptides much efficiently than the corresponding acetyl peptide on lysine 
residues (23). The Sirt5 catalyzed deacylation reaction and its mechanism are shown in 
Fig. 2.1. This finding was further corroborated by Zhang et al. who showed that many 
mammalian proteins are succinylated or malonylated (24). This new activity of Sirt5 led 
us to hypothesize that other sirtuins with weak deacetylase activity could also hydrolyze 
other acyllysine modifications.  
In this work, I specifically studied Sirt6 to explore whether it has any new activity. 
The biological functions of Sirt6 have been well described in literature (25-30). In most 
cases, the biological functions have been linked to the sequence specific deacetylase 
activity of Sirt6 on histone H3K9 and H3K56 peptide sequences, but not on other histone 
sequences. In this work, I found a novel activity for Sirt6. In particular, using the 
enzymology data, I established that Sirt6 prefers to hydrolyze longer chain fattyacyl 
modifications better than the shorter acetyl modification on lysine residues. In terms of 
the catalytic efficiency (kcat/Km), this new activity is comparable to other sirtuins with 
robust deacetylation activity (for example Sirt1-3). The sequence specificity of Sirt6 is in 
  
















Fig. 2.1 (A) The sirtuins catalyzed NAD-dependent deacylation reaction is shown, and 
the reaction generates O-acyl-ADP-ribose. (B) Mechanism of sirtuin catalyzed NAD-
dependent deacetylation. Some of the oxygen atoms are colored differently to indicate 
where they come from. 
 
contrast with other sirtuins (Sirt1, HST2), which possess robust deacetylation activity but 
show little preference for peptide sequences. I showed that human Sirt6 could 
accommodate sequences other than H3K9 and efficiently remove the myristoyl group 
from sequences like H2BK12 and H4K16. No hydrolysis by Sirt6 has been previously 
reported for the acetyl modified version of these peptides. Further, in collaboration with 
Wang et al., we crystallized Sirt6 with H3K9myr peptide. The crystal structure unveils a 
large hydrophobic pocket that can accommodate the long chain fattyacyl groups. This 
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further supported our enzymology data. Since Sirt6 has been known to be a nuclear 
protein and has been associated with histones, I also wanted to explore whether histones 
might have fattyacyl modifications as an epigenetic mark. In the results section, I present 
some of the key experiments that I performed towards that end. 
Later, my colleague Hong Jiang extended this work and showed that Sirt6 
promotes the secretion of TNFα by removing the fattyacyl modification on Lys19 and 
Lys20 of TNFα. Protein lysine fattyacylation has been known to occur in mammalian 
cells (31, 32) on the TNFα protein, but the regulatory mechanism of this modification was 
unknown. Together, our data suggest that protein lysine fattyacylation is a novel 
mechanism for regulating protein secretion. The discovery of Sirt6 as an enzyme that 
controls protein lysine fattyacylation provides new opportunities to investigate the 
physiological function of these previously less known PTMs. 
 
2.3 Methods and Materials 
 
Cloning, Expression, and Purification of Full Length Sirt6 for Activity Assay 
The open reading frame of full length human Sirt6 (1-355) was inserted into a 
pET28a vector between the BamHI and NotI sites. This plasmid was transformed in the 
E. coli ArcticExpress (DE3) cells. The cells were cultured at 37 °C in 2×YT culture 
medium (5 g of NaCl, 16 g of bactotrypton, and 10 g of yeast extract per liter). To induce 
the protein expression, isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added to a 
final concentration of 0.2 mM and when OD600 was 0.6-0.8, the culture was grown for 
another 48 h at 12 °C. Cells were harvested by centrifugation at 7,330 g for 10 min at 4 
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°C and then re-suspended in lysis buffer (20 mM Tris-HCl, pH 7.2, 500 mM NaCl and 
2% glycerol). The suspension was lysed using Avestin emulsiflex cell disrupter and then 
centrifuged at 29,300 g for 25 min at 4 °C. The supernatant was loaded onto a nickel 
column (QFF-sepharose, Amersham Biosciences, Sweden) pre-equilibrated with a buffer 
containing 20 mM Tris-HCl, pH 7.2, 500 mM NaCl. The target protein was eluted with a 
linear gradient of 0 to 500 mM of imidazole freshly prepared in the lysis buffer. The 
desired fractions were pooled, concentrated, and buffer exchanged against the cation 
exchange buffer (80 mM NaCl, 20 mM Tris-HCl, pH 7.2, 5% glycerol). The protein was 
then loaded onto a cation exchange column (Amersham Biosciences, Sweden) and was 
eluted with 1 M NaCl, 20 mM Tris-HCl, pH 7.2, 2% glycerol. Fractions were assayed for 
purity on SDS-PAGE gel, and the desired fractions were concentrated and stored at -80 
°C for later use. 
 
Activity Assay using LC-MS 
The activity of Sirt6 was determined using HPLC to separate the reaction mixture 
by detecting the modified and unmodified WWH3K9 peptides using a mass spectrometer 
coupled to it. The reaction comprised of 20 mM of Tris pH 8.0, 1 mM DTT, 50 µM 
WWH3K9 modified peptide, 0.5 mM of NAD and 2.8 µM of Sirt6 (truncated or full 
length) in a 60 µL reaction volume and was incubated at 37 
o
C for 1 h. The reaction was 
stopped with 1 volume of 0.5 N HCl in methanol (methanol was used to ensure the 
solubility of hydrophobic fattyacyl peptide) and spun down for 10 min at 18,000 g 
(Beckman Coulter Microfuge) to separate the protein from the reaction mixture. The 
supernatant was then analyzed by LC-MS on a SHIMADZU LC-MS-QP8000α with a 
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Sprite TARGA C18 column (40 × 2.1 mm, 5 µM, Higgins Analytical, Inc., Mountain 
View, CA). The LC was monitored at 215 and 280 nm. Solvents used in LC-MS were 
water with 0.1% formic acid and acetonitrile with 0.1% formic acid. 
 
Kinetic Assay for Acetyl and Butyryl Peptides 
The acetyl or butyryl peptides were dissolved in 25% DMSO water mixture. The 
concentrations of peptides were determined at 280 nm using extinction coefficient of the 
two tryptophan residues attached at the C-terminus of the peptides (since the tryptophan 
residues added to the peptides absorb predominantly at this wavelength). The final DMSO 
concentration in the reaction mixture was maintained at 2.5%. Peptide concentrations 
were varied from 0 to 250 μM for H3K9 butyryl peptide and from 0 to 600 μM for the 
acetyl peptide. The reactions containing 2 mM NAD, 1 mM DTT, 20 mM Tris, pH 8.0, 4 
μM recombinant Sirt6 full length, and acyl peptides at various concentrations were 
incubated for 30 min at 37 °C. The reactions were stopped using 1 volume of 0.5 N HCl 
in methanol. The reaction mixtures were spun at 18,000 g for 10 min and were analyzed 
on a Kinetex XB-C18 column (100 Å, 100 mm × 4.60 mm, 2.6 μm, Phenomenex). The 
gradient of 20-40% B in 17 min at 0.5 mL/min was used. The product peak and the 
substrate peak were quantified using absorbance at 280 nm and converted to initial rates. 
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Kinetic Assay for Long Chain Fattyacyl Peptides 
The longer chain fattyacyl peptides were dissolved in pure DMSO. The 
concentrations of peptides were determined at 280 nm using extinction coefficient of the 
two tryptophan residues attached to the C terminus of the peptides (since the tryptophan 
residues added to the peptides absorb predominantly at this wavelength). The final DMSO 
concentration in the reaction mixture was maintained at 2.5%. The peptide concentrations 
were varied from 1 to 20 µM. The reactions containing 2 mM NAD, 1 mM DTT, 20 mM 
Tris pH 8.0, 0.2 µM recombinant Sirt6 full length, and acyl peptides at different 
concentrations were incubated for 15 min at 37 °C. The reactions were stopped using 1 
volume of 0.5 N HCl in methanol. The reaction mixtures were spun at 18,000 g for 10 
min and were analyzed on Kinetex XB-C18 column (100 Å, 75 mm × 4.60 mm, 2.6 μm, 
Phenomenex). The gradient of 0-55% B in 10 min at 0.5 ml//min was used. The product 
peak and the substrate peak were quantified using absorbance at 280 nm and converted to 
initial rates. Initial rates were then plotted against the acyl peptide concentration and fitted 
using the software KaleidaGraph. 
 
Isolation of 2´-O Myristoyl ADP-ribose 
The reaction was carried out as described previously in the activity assay except 
that instead of 1 mM NAD, we used 0.25 mM NAD and 4 µM recombinant Sirt6 (1-314).  
The reaction was quenched using 10% TFA in 90% acetonitrile. The quenching solution 
was critical due to the hydrophobic nature and stability of the 2´-O-myristoyl ADP-ribose. 
The reaction was analyzed on reverse phase HPLC using C18 Vydac column (250 × 4.6 
mm, 90 Å, 10 µM, Grace Vydac, Southborogh, MA). A gradient of 0-40% B in 15 min, 
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10%-100% B in 15 min was used to separate the intermediate from the reaction mixture. 
The buffer A was water and 0.1% TFA and buffer B was 100% acetonitrile in 0.1% TFA. 
The myristoyl ADP-ribose was collected, lyophilized, and redissolved in 50% acetonitrile 
water and submitted for MALDI–TOF mass spectroscopy in the negative mode. 
 
32
P-NAD Radiolabeling Assay 
Different peptides (50 μM) were incubated with 2 mM DTT and 50 mM Tris pH 
8.0, 500 mM NaCl buffer, 1 μM Sirt6 and 0.1 μCi 32P-NAD (purchased from American 
Radiolabeled Chemicals Inc.) in a 10 µL reaction tube at 37
o
C for 2 h. Then, 1 µL of 
reactions mixture was spotted on a plastic backed silica gel TLC plate. The solvent 
system consisting of 70% ethanol and 30% 2.5 M ammonium acetate was used to resolve 
the reaction mixture. The 
32
P-NAD and products were detected by autoradiography.  
 
Digestion of Histone 
For trypsin digestion of calf thymus histone, 2 mg of the protein was dissolved in 
6 M urea, 60 mM Tris-HCl (pH 8.0), 15 mM DTT in a 250 µL reaction volume. The 
solution was heated at 37 °C for 30 min and then cooled to room temperature. Then, 22.5 
µL of 1 M iodoacetamide was added in order to achieve a final concentration of 
approximately 50 mM. The reaction mixture was incubated at room temperature with 
gentle mixing for 1 h in a dark tube. Then, 3.6 mL of 50 mM Tris-HCl (pH 7.4) with 1 
mM CaCl2 was added to the reaction mixture to lower the urea concentration to 0.75 M. 
For the digestion step, 150 µL of 100µg/mL modified and activated trypsin 
(Promega Corporation, Madison, WI) was added and the reaction mixture was incubated 
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at 37 °C for 12-16 h. The reaction was quenched by adding 120 µL 10% TFA and the pH 
was adjusted to 2~3. The digested peptides were desalted by using Sep-Pak C18 cartridge 
1 cc/50 mg (Waters Corporation, Milford, MA) and lyophilized in glass vials. All the 
steps were performed as per the instructions on the cartridge. However, the elution step 
was modified in which instead of the usual 50% acetonitrile-water, another elution was 
performed with 90% acetontrile-water to ensure the elution of the hydrophobic peptides. 
The eluted peptides were lyophilized in glass vials and dissolved in minimum amount of 
water or dimethylsulfoxide. 
 
Peptide Synthesis  
The WWH3K9 (NH2-KQTARK*STGGWW-COOH) backbone was prepared 
using standard solid phase peptide synthesis (SPPS) at room temperature (RT). Briefly, 
100 mg Wang resin SS (100-200 mesh, 1% DVB, 10 mMole/g) was swollen in a peptide 
synthesis vessel with 5 ml of anhydrous dichloromethane (DCM) for 5 h. After draining 
off the solvent, resin was washed with 5 ml N, N-dimethylformamide (DMF). The 
reaction mixture containing the first amino acid namely Fmoc-tryptophan-OH (0.32 
millimoles, 3 equivalents) along with O-benzotriazole-N, N, N´, N´-tetramethyl-uranium-
hexafluoro-phosphate (HBTU, 0.133 millimoles, 1 equivalent) and 4-
dimethylaminopyridine (DMAP) was dissolved fully in 5 ml of anhydrous DMF. To this, 
0.64 millimoles of diisopropylethylamine (DIEA) were added as base and the reaction 
mixture solution was then added to the resin. The resin was incubated with the solution 
overnight at RT. The resin was washed with 5 ml DMF for 5 times. The excess reactive 
functionalities on the resin were blocked using a solution of acetic acid, pyridine, and 
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DMF in 2:1:3 ratios, respectively for 30 min. After draining off the blocking solution, the 
resin was washed and Kaiser test reference was used to test the success of the coupling. 
Once coupling was confirmed, the resin was treated with a 20% piperidine in DMF 
solution for 5 min to remove the Fmoc group. The treatment with piperidine was repeated 
for 20 min for the second time with a fresh batch of piperidine in DMF solution in order 
to ensure a full deprotection. The resin was washed three times with DMF, and then again 
three times with DCM, a Kaiser test was performed at this point to ensure that the 
deprotection worked.  Finally, the resin was washed three times with DMF before adding 
the next amino acid again. All subsequent activated amino acid derivatives were freshly 
prepared by dissolving 0.24 millimoles of the amino acid, 0.24 millimoles of HBTU, and 
0.21 millimoles of N-hydroxybenzotriazole (HOBT) in 5 ml of DMF. Lastly, 0.48 
millimoles of DIEA was added to above mixture and the resulting solution was in turn 
added to the resin. The suspension was incubated for at least 2 h at RT. 
The lysine to be modified by different acyl groups (K*) was protected with Alloc 
on the side chain while the N-terminal lysine was protected by Boc at both the side chain 
and at the amino group terminus. After the addition of all the amino acids, the Alloc 
group was removed using a solution of DCM, morpholine (Sigma, 2.5% v/v), and glacial 
acetic acid (5% v/v) with a 1:1 (w:w) ratio of the original resin and tetrakis 
(triphenylphosphine) palladium(0) for 4 h under nitrogen at RT. The resin was washed 
with 0.5% DIEA in DCM for 5 min and the washing was repeated five times. The resin 
was again washed at least two times with 0.02 M of diethyldicarbamate in DMF, each 
time for 30 min to remove the palladium. The resin was subjected to the acylation 
solutions containing 0.24 mMoles fatty acid of different chain lengths (acetic anhydride, 
  31 
butyric acid, octanoic acid, myristic acid, dodecanoic acid, palmitic acid etc.), 0.24 
mMole of HBTU, 0.21 mMole of HOBT, 0.48 mMole of DIEA, and anhydrous DMF 
overnight at RT. The resin was then washed with DMF and DCM in that order. To cleave 
the peptide from the resin, the dried resin was subjected to a concoction of TFA, 5% 
water, 5% phenol, 2.5% ethanedithiol, and 5% thioanisole for 2-4 h at RT. The solution 
containing the cleaved peptide was filtered and the TFA was removed by flushing N2 gas 
or air over the filtrate. The peptide was precipitated by adding ether three times. Ether 
was then removed by decantation and the crude peptide was lyophilized. The crude 
peptide was dissolved in water containing 1% TFA, was subjected to HPLC (Beckman 
Coulter System Gold 125P solvent module and 168 Detector) separation. The HPLC 
separation was done on TARGA C18 column (250 x 20 mm, 10 μM, Higgins Analytical, 
Inc., Mountain View, CA) with mobile phase A (water with 0.1% TFA) and B 
(acetonitrile with 0.1% TFA) at a gradient of 20% B to 100% B in 50 min and a flow rate 
of 10 mL/min. The peptide was monitored at both 215 nm and 254 nm, and the fractions 
were collected. LC-MS (SHIMADZU LC-MS-QP8000α with a Sprite TARGA C18 
column (40 × 2.1 mm, 5 m, Higgins Analytical, Inc., Mountain View, CA) was used to 
confirm the peptide mass and the high purity fractions were lyophilized. For the LC-MS 
runs, the peptide could be observed at both 215 nm and 280 nm, and the solvents used 
were water with 0.1% formic acid and acetonitrile with 0.1% formic acid. Purified 
peptide was either dissolved in water or in DMF and the concentration was determined 
using UV spectroscopy. Other peptides were synthesized similarly as described above. 
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2.4 Results 
Sirt6 was first expressed in Escherichia coli Rosetta (E. Coli BL21R2-DE3) cells. 
However, since the full length protein was not stable, very little soluble protein was 
obtained from these cells. The truncated form of Sirt6, Sirt6 (1-314), with the conserved 
core catalytic domain still intact was expressed. The truncated protein was obtained using 
Ni-resin purification followed by gel-filtration purification as shown in Fig. 2.2. 
 
Fig. 2.2 Ni – NTA affinity purification of human Sirt6 (1-314) in E. coli BL21R2 cells; 
the expected molecular weight is 39 kDa. 
 
Sirt6 has been previously known to be sequence specific in its deacetylase activity 
for H3K9 and H3K56 histone peptides (19, 20, and 27). We therefore chose the H3K9 
peptide as our model for the peptide backbone with K9 being the site for different 
physiologically relevant modifications, namely acetylation, propionylation, butyrylation, 
biotinylation, lipoylation, glutrylation, SUMOylation, and ubiquitylation. The 
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SUMOylation and ubiquitylation meant small peptide sequences (i.e. for SUMO1 
NH2DVIEVYQEQTGG and for NEDD8 NH2LHLVLALRGG) from the SUMO and 
ubiquitin proteins as the „acyl‟ modifications on K9 of the H3K9 peptide. A small peptide 
library, as shown in Fig. 2.3, was generated using the synthesis scheme as described in the 
literature (33). The synthesized peptides were subjected to reverse phase HPLC 
purification. Identity of the peptides was confirmed using mass spectroscopy. Table 2.1 




Fig. 2.3a Synthesis scheme for making the „acyl‟ peptide library on the lysine 9 of the 
histone H3K9 peptide sequence.  




Fig. 2.3b Various peptides made using the scheme as described above. 
 
 







Peptide  Sequence 
H3K9Acetyl 1274.0 1273.71 KQTAR(AcK)STGGKA 
H3K9Propionyl 1287.8 1288.73 KQTAR(ProK)STGGKA 
H3K9Lipoyl 1422.15 1419.73 KQTAR(LipK)STGGKA 
H3K9Biotin 1457.85 1457.78 KQTAR(BiotinK)STGGKA 
H3K9Transoctenoic  
Acid 
1355.75 1355.79 KQTAR(OctenoicK)STGGKA 
H3K9Myristoyl 1441.95 1441.9 KQTAR(MyrK)STGGKA 
H3K9Palmitoyl 1470.25 1469.93 KQTAR(PalmK)STGGKA 
H3K9HMG 1375.2 1375.74 
KQTAR(HMGK)STGGKA 
HMG -Hydroxymethyl glutarate 
H3K9SUMO1 1387.20 2772.37 
*KQTAR(SUMO1K)STGGKA 
       SUMO-1:DVIEVYQEQTGG 




*KQTAR(SUMO2K)STGGKA    
SUMO-2: IDVFQQQTGG 
             *K is Fmoc protected 
H3K9NEDD8 1800.072 1799.049 
KQTAR(NEDD8K)STGGKA 
NEDD8: LHLVLA 
H2BK12Acetyl 1831.05 1832.05 
PEPAKSAPAPKK(Ac)GSKKW
W 
H2BK12Myristoyl 2000.05 2000.24 
PEPAKSAPAPKK(Myr)GSKK
WW 
H3K9Acetyl 1447.67 1446.74 KQTAR(AcK)STGGWW 
H3K9Butyryl 1475.42 1474.77 KQTAR(ButK)STGGWW 
H3K9Octanoyl 1532.67 1530.83 KQTAR(OctK)STGGWW 
H3K9myristoyl 1616.5 1614.9 KQTAR(MyrK)STGGWW 
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The activity of the recombinant Sirt6 (1-314) on these different acyl peptides was 
assessed by using a high-performance liquid chromatography (HPLC) based in vitro assay 
coupled to a mass spectrometer (details of the activity assay are described in Section 2.3). 
The truncated Sirt6 (1-314) was indeed found to deacylate comparatively longer chain 
fattyacyl groups such as palmitoyl, myristoyl, and lipoyl peptides better than the acetyl, 
succinyl, glutaryl, and ubiquitylated H3K9 peptides (Table 2.1). The following figures 
show the LC-MS traces of the activity assay for some of the acyl peptides. The vertical 
axis in the figures shows the ion intensities (10 × magnified) and the horizontal axis show 
the retention time of the acylated and deacylated peptides. The mass of the acylated 
peptides are shown in Table 2.1 and that of the deacylated peptide is 1232.0. The activity 
for different peptides was detected by the presence of deacylated peptide mass intensities, 
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Fig. 2.4 Sirt6 (1-314) catalyzes the hydrolysis of myristoyl lysine on the histone H3K9 
based sequence. Sirt6 and Sirt5 catalyzed reactions were analyzed by LC-MS, with Sirt5 
being the positive control for desuccinylation (Fig. 2.4A).  For each reaction, the MS 
trace (Fig. 2.4A-2.4G) shows the ion intensities (10 × magnified) for the acylated peptides 
and the deacylated peptides.  
 
To facilitate the UV detection of the peptides, two tryptophan residues were added 
to C terminus of the H3K9 backbone peptide. This enabled the detection of peptides in 
the kinetic assay as described in Section 2.3. The H3K9 and WWH3K9 peptides were 
used interchangeably in all assays and the choice has been marked clearly in all figures 
described in this thesis. 
In order to further confirm the results from the activity assays described above, a 
32
P-NAD-based biochemical assay was used. Based on the known deacylation mechanism 
of sirtuins (Fig. 2.1 B), the demyristoylation of the fattyacyl H3K9 peptide by Sirt6 
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should generate 2´-O-myristoyl ADP-ribose. When incubating myristoyl H3K9 with Sirt6 
(1-314) and 
32
P-NAD, most of the NAD was consumed and a new very less polar spot 
that ran almost at the solvent front was observed (Fig. 2.5). This is consistent with the 
formation of 2´-O-myristoyl ADP-ribose, since the hydrophobic myristoyl will make the 
intermediate acyl-ADP-ribose less polar. When acetyl H3K9 peptide was incubated with 
Sirt6 (1-314) and 
32
P-NAD, although a new product (2´-O-acetyl ADP-ribose) spot was 
observed, there were still NAD molecules left. The data suggested that Sirt6 catalyzed 
demyristoylation is more efficient than deacetylation. 
 
 
Fig. 2.5 Biochemical 
32
P-NAD assay of the Sirt6 (1-314) with various H3K9acyl 
peptides, which shows the formation of less polar 2´-O-fattyacyl-ADP-ribose. 
 
We also confirmed the formation of the 2´-O-myristoyl-ADP-ribose obtained from 
the in vitro assay using MALDI – TOF mass spectroscopy (Fig. 2.6a-c). Firstly, the 
reaction intermediate was isolated. Two main challenges of isolating this reaction product 
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were its stability and solubility in our acidic quenching solution (0.5 N HCl in methanol). 
To isolate the 2´-O-myristoyl-ADP-ribose intermediate, we switched to a milder 
quenching solution of 10% TFA in 90% acetonitrile-water. The intermediate was isolated 
by separating the reaction mixture using reverse phase HPLC (Fig. 2.6a). The isolated 
intermediate was lyophilized and subjected to MALDI-TOF mass spectrometry in the 
negative mode. The presence of O-myristoyl-ADP-ribose was verified by the presence of 





Fig. 2.6a HPLC trace for the separation of 2´-O-myristoyl-ADP-ribose from the reaction 
mixture. 
 
  42 
 
Fig. 2.6b MALDI-TOF spectra for the O-myristoyl-ADP-ribose peak collected from the 
positive control (reaction mixture with Sirt6) shows the presence of desired mass peak 
with m/z of 768.31. 
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Fig. 2.6c MALDI-TOF spectra for the O-myristoyl-ADP-ribose peak collected from the 
negative control (reaction mixture without Sirt6) shows no mass peak corresponding with 
m/z of 768.31. 
 
        After determining the more efficient activity for Sirt6, I tested whether the new 
defattyacylation activity would allow Sirt6 to accept other peptide sequences as substrates 
as is the case with other sirtuins (Sirt1-3), which are known to have a strong deacetylation 
activity but no specificity. For this purpose, I synthesized acetyl and myristoyl peptides 
based on H2BK12 and H4K16 histone sequences (Table 2.1). Consistent with the earlier 
report (20), the hydrolysis of these acetyl peptides by Sirt6 was essentially undetectable 
based on the HPLC analysis. In contrast, the hydrolysis of the corresponding myristoyl 
peptides can be readily detected (Fig. 2.7). This activity was also confirmed by detecting 
the mass of the hydrolyzed or deacylated peptide using HPLC analysis coupled with mass 
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spectroscopy or LC-MS assay (data not shown). These results further support that the 
defattyacylase activity of Sirt6 is more efficient than its deacetylase activity. We hence 
concluded that with the appropriate acyl group, Sirt6 can catalyze the hydrolysis of acyl 







Fig. 2.7 HPLC traces for the hydrolysis of H2BK12 and H4K16 acetyl and myristoyl 
peptides by Sirt6 (1-314). The formation of demyristoylated peptides was confirmed 
using mass spectroscopy (data not shown here). 
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Once I fully confirmed the demyristoylation activity of the truncated Sirt6 (1-
314), I also expressed the full length Sirt6 in E. coli strain of BL21DE3 ArcticExpress 
(AE) cells. My aim was to use different chain length H3K9 acyl peptides to test the same 
activity with the full length version of the protein and to determine the exact kinetic 
parameters for the same.  
I re-established that the full length Sirt6 can hydrolyze long chain fattyacyl groups 
from WWH3K9 peptides much better than WWH3K9acetyl peptide as shown in Fig. 
2.8A. Fig. 2.8B demonstrates that the full length Sirt6 can accommodate other peptide 
sequences also such as WWH2BK12myr. The activity found (Fig. 2.8A) was further 










increased catalytic efficiency comes mainly from the decrease in Km. The better binding 
affinity for longer chain fattyacyl groups is due to the presence of long hydrophobic 
pocket in the substrate binding pocket, which is absent in other sirtuins. For the acetyl 


















































Fig. 2.8 Sirt6 prefers to hydrolyze long chain fattyacyl lysine in vitro. Panel A shows 
HPLC traces of Sirt6 catalyzed hydrolysis of different acyl peptides based on the H3K9 
sequence. Panel B shows H2BK12 myristoyl peptide can be hydrolyzed by Sirt6 while 
the corresponding acetyl peptide cannot. 
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Acetyl (C2) 0.0039±0.0006 810±160 4.8 
Butyryl (C4) 0.0021±0.0004 200±120 10 
Octanoyl (C8) 0.0046±0.0005 40±10 1.2×10² 
Myristoyl (C14) 0.0049±0.0004 3.4±0.9 1.4×10³ 
Palmitoyl (C16) 0.0027±0.0002 0.9±0.4 3.0×10³ 
 
Table 2.2 Catalytic efficiencies of Sirt6 on different acyl peptides. 
  
In order to understand the preference of Sirt6 for medium and long chain fattyacyl 
groups, the truncated form of Sirt6, Sirt6 (1-294), was crystallized in collaboration with 
Yi Wang
*
. The Sirt6 (1-294) was complexed with H3K9myr peptide and ADP-ribose. 
The structure was determined at 2.2 Å resolution (Fig. 2.9) and it was found to be similar 
to the earlier published apo Sirt6 structure (34). However, residues 2-10 and 166-174 of 
Sirt6 are visible in the H3K9 myristoyl bound crystal structure, while the corresponding 
regions are missing in the published apo Sirt6 structure. 
 
                                                 
*
 Quan Hao, Yi Wang ,Department of Physiology, University of Hong Kong, Hong Kong, China 




Fig. 2.9A Crystal structure of the full length Sirt6 complexed with H3K9myristoyl 
peptide (green) and ADP-ribose (yellow) at 2.2 Å resolution.  
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Fig. 2.9B Acyl pocket of the full length Sirt6 complexed with H3K9myristoyl peptide and 
ADP-ribose at 2.2 Å resolution. The residues highlighted in orange form hydrophobic 
pocket which can accommodate the myristoyl side chain shown in green. 
 
There are two features in the crystal structure that explain the enzymology data. 
Firstly, the peptide interacts with Sirt6 through hydrogen bonding interactions similar to 
those observed in other sirtuins including Sirt5. Most of the hydrogen bonds come from 
the main chain C=O and N-H of the H3K9 myristoyl peptide, with the only side chain 
hydrogen bonding interactions coming from Trp11. Therefore, it appears that the 
selectivity for peptide sequences is not high. Secondly, the hydrophobic pocket, which 
accommodates the myristoyl group, is comprised of Ala11, Pro60, Phe62, Trp69, Pro78, 
Phe80, Phe84, Val113, Leu130, Leu184, and Ile217 hydrophobic residues. These residues 
form different flexible loops which are absent in other sirtuins. 
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The presence of fattyacyl CoAs in cells as metabolites and the fact that Sirt6 could 
efficiently remove long chain fattyacyl groups from lysine residues suggest that the lysine 
fattyacylation might be a more prevalent PTM than originally thought. Lysine 
myristoylation, although not widely known, was reported to occur in a few proteins such 
as interleukin α and TNFα (31, 32). Sirt6, known as a nuclear protein, was thought to 
remove modifications on histones (19, 20, 22). Also, there were reports that lysine 
propionylation and butyrylation occurred on the core histone H4 proteins (35). 
Proteomics study by Hang et al. suggested S-acylation might be present on some variants 
of H3 histones (36). With the backing of these findings, it was compelling to hypothesize 
that firstly, fattyacylation occurs on histone lysine residues and is an unrecognized 
epigenetic modification, and secondly, Sirt6 hydrolyzes the fattyacylation on histone 
lysines. Therefore, to seek the substrate for Sirt6, we focused on histones as a possible 
candidate. However, because lysine fattyacylation was not a very well recognized 
modification (9, 32), there were no antibodies present to probe this modification at the 
protein level.  
 At about the same time, Zhu et al. were studying PfSir2a (Sirt6 homolog in 
malaria parasite Plasmodium falciparum) and had detected a robust defattyacylation 
activity for H3K9 fattyacyl peptides (37). PfSir2a was more stable and sensitive in the 
radiolabeling assay than Sirt6 (1-314). This fact enabled us to use it for detecting whether 
or not lysine modification was present in histones. We started with the commercial calf 
thymus histone because it could be obtained easily in a reasonable quantity. Our goal was 
to digest the commercial calf thymus histone into peptides, and then test these digested 
peptides for fattyacylation mark using 
32
P-NAD based biochemical radiolabeling assay. 
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The reason for the choice of 
32
P-NAD biochemical radiolabeling assay was due to low 
levels of these modifications it could detect. The detection limits of this assay from the 
reaction of wwH3K9myristoyl peptide with pfSir2a and Sirt6 enzymes were found to be 
0.03 μM peptide per 1 μM pfsir2a and 0.1 μM peptide per 1 μM Sirt6, respectively. The 
desired peptides would then be subjected to LC-MS/MS in order to confirm the 
modification. However, due to the hydrophobicity of the modification, we needed to 
modify and standardize the known techniques. The commercial calf thymus histone was 
trypsin digested and the digested mixture was desalted using sep pak C18 column (Waters 
Inc.). Using 50% and 90% acetonitrile-water, digested peptides were eluted as shown in 
Fig. 2.10a. The idea was to use a higher acetonitrile percentage (90% against the usual 
50%) to elute more hydrophobic peptides. Elutions were also done using a blank cartridge 
as control. 
 
Fig. 2.10a Sample preparation for the detection of fattyacyl ADP-ribose from commercial 
calf thymus histones using
 
trypsin digestion. 





P-NAD radiolabeling assay with digested calf thymus histones shows the 
formation of fattyacyl ADP-ribose, when the 90% acetonitrile-water eluent is incubated 




 The peptides were lyophilized in glass vials (because hydrophobic peptides would 
stick to the plastic eppindorf tube). Dimethylsulfoxide was used for dissolving lyophilized 
peptides. 
32
P-NAD radiolabeling biochemical assay was done with the recombinant 
pfSir2a as the defattyacylating enzyme. The idea was to see if we could observe the 
highly nonpolar 2´-O-fattyacyl ADP-ribose spot, since it would signify that fattyacylation 
is present on the calf thymus histones. It did show a highly non-polar fattyacyl ADP-
ribose spot, which indicated that the commercial calf thymus histones might have the 
lysine fattyacylation (Fig. 2.10b). To confirm this, the digested peptides were subjected to 
LC-MS/MS using a gradient different from the one normally used. The gradient used 
went up to 90% acetonitrile-water. However, no fattyacylation could be detected. This 
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was mainly due to the inconsistency in fragmentation pattern for even the standard H3K9 
myristoylated peptide and also the low abundance of the fattyacylated peptides.  
 Later on, my colleague Hong Jiang proposed that Sirt6 may regulate TNFα 
secretion via defattyacylation based on two reports (38, 39). These reports indicated that 
Sirt6 can regulate the synthesis of secreted TNFα. However, the mechanism was unclear. 
TNFα is a type II membrane protein with a single transmembrane domain connecting the 
intracellular N terminus with extracellular C terminus (40). It was already known that 
TNFα protein was myristoylated at Lys19 and Lys20 positions. Therefore, we 
hypothesized that Sirt6 may regulate TNFα secretion via defattyacylation. In order to test 
the hypothesis at the biochemical level, I synthesized a TNFα peptide with myristoyl 
modification at Lys19 and Lys20 positions and performed the kinetic study using the 
HPLC-based activity assay as described in Section 2.3. The catalytic efficiency (i.e. 
kcat/Km) was approximately 250 times higher than that for the H3K9 acetyl peptide and 









TNFK20myristoyl 0.005±0.0004 4.5±1.1 1.1×10³ 
TNFK19myristoyl 0.0020±0.0002 2.4±0.6 8.3×10² 
 
Table 2.3 Catalytic efficiencies of Sirt6 on TNFα peptides. 
 
 The rest of the experiments to test the hypothesis were performed by Hong Jiang 
and are described as follows. The hypothesis was tested on the cellular level by 
comparing the fattyacylation level of TNFα in Sirt6 WT MEF and Sirt6 KO MEF cells. 
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For this purpose, we used fattyacyl analogues to covalently label TNFα using a known 
scheme (41). The cells transfected with epitope tagged TNFα were cultured in the 
presence of fattyacyl analogues with an alkyne tag. The TNFα was then immuno-
precipitated and conjugated to rhodamine azide using the click chemistry. The labeled or 
the fattyacylated proteins were visualized by fluorescence. To rule out the possibility of 
visualizing cysteine fattyacylation, the immuno-precipitated proteins were treated with 
hydroxyl amine in order to hydrolyze the cysteine fattyacylation prior to the visualization. 
Using fluorescence detection, it was found that WT TNFα obtained from the Sirt6 KO 
cells showed more labeling than that obtained from the Sirt6 WT MEF cells. It was also 
found that when mutating Lys19 and Lys20 of TNFα (sites of lysine myristoylation) to 
arginine, the labeling intensities dropped to the background level for the Sirt6 KO cells. 
This particular data confirmed the presence of lysine fattyacyl modifications at Lys19 and 
Lys20 residues of TNFα. Further, it was demonstrated in an in vitro assay that Sirt6 
defattyacylation of TNFα (obtained from the Sirt6 KO MEF cells) was dependent on 
NAD
+
. This data corroborated our finding from kinetic data on the TNFα peptides (Table 
2.3) that Sirt6 defattyacylated TNFα through its NAD+-dependent deacylation activity. 
Finally, to test the hypothesis that Sirt6 controlled TNFα secretion, FLAG-tagged TNFα 
was expressed in the Sirt6 KO and WT cells. The secretion efficiency was calculated by 
measuring the TNFα present in the cells and that present in media using ELISA based 
assay. The secretion efficiency was found to be less in Sirt6 KO MEF cells than the Sirt6 
WT MEF cells. It was also found that the secretion of TNFα mutant did not show any 
difference in the WT and Sirt6 KO MEF cells. This established that the secretion is 
indeed controlled by the fattyacylation level of TNFα, which is in turn controlled by 
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defattyacylation activity of Sirt6. Since all the above studies were in the MEF cells with 
over expressed TNFα, the hypothesis was further extended on the endogenous TNFα 
obtained from the human acute monocytic leukemia (THP-1) cells and the mouse 
macrophages.  Two Sirt6 KD cell lines were created using two short hairpin (sh) RNA 
and a control was generated using a control shRNA. Using the same labeling method as 
described above, it was observed that TNFα fattyacylation was higher in Sirt6 KD THP-1 
cells than the control KD THP-1 cells. Using the ELISA assay, the amount of TNFα 
secreted in the media and the amount that remained in the cell were measured. Using the 
two values, the secretion efficiency was calculated. Secretion efficiency of TNFα was 
found to be greater in the Sirt6 KD THP-1 cell line in comparison to the control KD THP-
1 cell line. Finally, to show that this finding is relevant at the cellular level, it was further 
demonstrated that Sirt6, which was thought to be a nuclear protein earlier, is also present 
in the endoplasmic reticulum, a central organelle for protein secretion. 
 
2.5 Discussion 
The biochemical and structural studies demonstrate that human Sirt6, which was 
known to have a weak deacetylase activity, can hydrolyze the longer chain fattyacyl 
groups much more efficiently than the shorter acetyl group. The kinetic parameters 
indicate that the defattyacylase activity of Sirt6 is comparable to the robust deacetylation 
activity of  other sirtuins, Sirt1-3. The higher catalytic efficiency results from the lower 
Km value. The mechanism for defattyacylation activity of Sirt6 is similar to the 
mechanism for deacetylation activity of other sirtuins. This is demonstrated by the 
biochemical radiolabeling assay and further confirmed by subjecting the isolated O-
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fattyacyl-ADP-ribose intermediate to MALDI-TOF spectroscopy.  However, the presence 
of longer catalytic pocket comprising of hydrophobic residues accommodates the 
fattyacyl modification, resulting in better binding affinity and robust defattyacylation 
activity. This long hydrophobic pocket is absent in other sirtuins, and therefore myristoyl 
or other fattyacyl groups are too long to fit in the catalytic pocket of most sirtuins. 
Based on our work on histones and the recent report (36), it is possible that 
histones might be fattyacylated too. A further investigation with better detection 
techniques and LC-MS/MS methods might be helpful in exploring this idea. It is possible 
that the two activities, defattyacylation and deacetylation might work together depending 
on the conditions. We further demonstrate physiological relevance of this novel 
defattyacylase activity of Sirt6 in defattyacylating TNFα at Lys19/Lys20 position. This in 
turn regulates the secretion of TNFα. Since TNFα is central to many signaling pathways 
and is an important mediator of inflammation response, further investigations might shed 
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CHAPTER 3 
Study of Defattyacylase Activity of Sirt6: Partial Results and Possible Extensions   
 
3.1 Introduction 
The sirtuin family of enzymes has been known as NAD-dependent deacetylases, 
though some of them have very weak or no detectable deacetylase activity. Sirt6 is 
important for DNA repair, transcription, metabolism, and life span expansion mainly 
because of its deacetylase activity.  In Chapter 2, I showed that Sirt6 possesses a new 
activity by removing long chain fattyacyl group from protein lysine residues and has a 
role in promoting TNFα secretion (1). In this chapter, I mainly studied two extensions of 
the previous work related to the defattyacylase activity of Sirt6: 
1. To obtain Sirt6 mutants responsible for the defattyacylase activity - In the crystal 
structure shown in the previous chapter (Fig. 2.9B), the acyl pocket for Sirt6 
contains a number of hydrophobic residues. My aim was to mutate some of these 
residues, namely Leu9 (not shown in Fig. 2.9B), Phe82, Phe86, and Val115 to the 
more hydrophilic residue arginine and to check the effect of these mutations on 
the preference of Sirt6 for long chain acyl peptides. Finally, we wanted to test the 
effects of these mutants on TNFα secretion. The goal was to identify an inactive 
mutant. 
2. The recent reports by Garabunova et al. (2, 3) showed that Sirt6 promoted DNA 
repair during oxidative stress by activating Poly ADP-ribose polymerase-1 
(PARP-1). This function has been attributed to the ADP-ribosoyl transferase 
activity of Sirt6, which was earlier thought to be too weak to be relevant in the 
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physiological context (4, 5).  It was reported that during oxidative stress, Sirt6 
activates PARP-1 by mono-ADP-ribosylating it. PARP-1 would in turn ADP-
ribosylate itself and other proteins, thereby promoting DNA DSB repair. I wanted 
to explore the efficiency of the self ADP-ribosylation activity of Sirt6 in 
comparison to the diphtheria toxin (DT) catalyzed ADP-ribosylation of elongation 
factor 2 (EF-2). I was also interested in knowing whether the mutants G60A and 
R65A mentioned above would affect the defattyacylase activity and whether it is 
possible that Sirt6 regulates PARP-1 by defattyacylation instead of mono-ADP-




Cloning and Transformation 
 The mutation in hSirt6 gene L9R was done using the stratagene quickchange 
method as described in the manual (6) except for the transformation part. The dsDNA 
template used was hSirt6 in pET28a (+) vector. The cycling parameters were taken from 
the Stratagene manual and the extension time used was 6 min. The mutated plasmid was 
digested using Dpn1 enzyme for 1 h at 37 ºC and 1 µL of the Dpn1 digested reaction 
mixture was transformed into Lucigen 10 G Solo chemically competent cells. The 
successful transformants were selected by plating the cells on kanamycin (50 mg/ml) 
Luria broth (LB) plates. The presence of the mutated gene was confirmed using 
Sanger/3730XL DNA sequencing. The primers used are described below and were 
purchased from Integrated DNA Technology (IDT). 




The other two single mutations in Sirt6 gene, V115R and F82R, were prepared by 
the overlap extension PCR method using Accuprime pfx enzyme (Invitrogen). The 
mutated gene was cloned into pET28 a (+) vector between the BamH1 and Not1 
restriction sites and ligated using quick ligase enzyme. The Sirt6 single mutant expression 
vectors were transformed into Lucigen 10 G solo chemically competent cells and selected 
by plating the cells on kanamycin (50 mg/ml) LB plates. The presence of the mutated 
gene was confirmed using Sanger/3730XL DNA sequencing. The primers used are listed 





SK001S56Y 5‟ cacacgggtgccggcatcTACactgcctctggcatcccc; 
SK002 3‟ gatgccggcacccgtgtg; 
SK005G60A 5‟ ggcatcagcactgcctctGCC atccccgacttcaggggtc; 
SK006 G60AG3‟ agaggcagtgctgatgcc; 
SK007 H133Y 5‟ ggacaaactggcagagctcTAC gggaacatgtttgtggaagaa; 
SK008 H133Y3‟ gagctctgccagtttgtcc; 
SKR65A0245'; ctctggcatccccgacttcGCCggtccccacggagtctgg; 
SKR65A025 3'; gaagtcggggatgccagag; 
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Transformation in ArcticExpress Cells 
The hSirt6 mutant expression vectors were transformed in the E. coli Rosetta 
ArcticExpress (DE3) cells at 42 °C for 90 s followed by recovery with 900 µL of 2 × YT 
media. The successful transformants were selected by plating the cells on kanamycin (50 
mg mL
–1
) and gentamycin (10 mg mL
–1
) LB plates. Single colonies were selected and 
grown in 2 × YT media with kanamycin (50 mg mL
–1
) and gentamycin (10 mg mL
-1
) as 
antibiotics overnight at 37 °C. On the following day, the cells were sub-cultured (1:1000 
dilution) into 2 L of 2 × YT media with kanamycin (50 mg mL
–1
) and gentamycin (20 mg 
mL
–1
). To induce the expression of desired protein, the cell culture was cooled to 12 ºC 
and isopropyl-d-1-thiogalactopyranoside (IPTG) was added to a final concentration of 0.2 
mM when OD600 was 0.6 - 0.8. The culture was grown for another 40 h at 12 ºC. 
 
Purification 
Cells were harvested by centrifugation at 7,330 g for 10 min at 4 °C and then 
resuspended in lysis buffer (20 mM Tris-HCl, pH 7.2, 500 mM NaCl and 2% glycerol, 10 
µL buffer saturated PMSF solution in ethanol per 50 ml lysis buffer). The suspension was 
lysed using an EmulsiFlex-C3 cell disruptor (AVESTIN Inc.) and then centrifuged at 
29,300 g for 35 min at 4 ºC in order to remove the cell debris. The supernatant was loaded 
into the column pre-equilibrated with Ni-NTA resin (Qiagen) in lysis buffer. The target 
protein was eluted using 100 mM imidazole solution in 20 mM Tris-HCl pH 7.2, 500 mM 
NaCl and 2% glycerol.  The desired fractions were pooled, concentrated, and buffer 
exchanged against the cation exchange buffer (80 mM NaCl, 20 mM Tris pH 7.2, 2% 
glycerol). The protein was then loaded onto a cation exchange column (Amersham 
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Biosciences) and was eluted with 1 M NaCl, 20 mM Tris-HCl, pH 7.2, 2% glycerol. 
Fractions were assayed for purity on SDS-PAGE gel and were concentrated and stored at 
-80 ºC.  
 
Activity Assay 
Activities of Sirt6 mutants S56Y, R65A, G60A, and H133Y were determined 
using HPLC to separate the reaction mixture detecting the modified and unmodified 
WWH3K9 peptide. The reaction mixture comprised of 20 mM of Tris pH 8.0, 1 mM 
DTT, 50 µM WWH3K9 modified peptide, 0.5 mM of NAD, and 2.8 µM of Sirt6 mutants 
and was incubated at 37 ºC for 1 h. The reaction was stopped with 1 equivalent of 0.5 N 
HCl in methanol and spun down for 10 min at 18,000 g (Beckman Coulter Microfuge) to 
separate the protein from the reaction mixture. The supernatant was then analyzed by 
HPLC using the unmodified WWH3K9 peptide as a standard for the decaylation product. 
 
Kinetic Assay for Acetyl and Butyryl Peptides 
The acetyl or butyryl peptides were dissolved in 25% DMSO water mixture. The 
concentrations of peptides were determined at 280 nm using extinction coefficient of the 
two tryptophan residues attached at the C terminus of the peptides (since the tryptophan 
residues added to the peptides absorb predominantly at this wavelength). The final DMSO 
concentration in the reaction mixture was maintained to be 2.5 %. Peptide concentrations 
were varied from 0 to 250 μM for WWH3K9 butyryl peptide and from 0 to 600 μM for 
the WWH3K9 acetyl peptide. The reactions containing 2 mM NAD, 1 mM DTT, 20 mM 
Tris, pH 8.0, 4 μM recombinant full length Sirt6, and acyl peptides at various 
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concentrations were incubated for 30 min at 37 °C. The reactions were stopped using 1 
volume of 0.5 N HCl in methanol. The reaction mixtures were spun at 18,000 g for 10 
min and were analyzed using a Kinetex XB-C18 column (100 Å, 100 mm × 4.60 mm, 2.6 
μm, Phenomenex). The gradient of 20-40% B in 17 min at 0.5 mL/min was used. The 
product peak and the substrate peak were quantified using absorbance at 280 nm and 
converted to initial rates. Initial rates were then plotted against the acyl peptide 
concentration and fitted using the software KaleidaGraph. 
 
Kinetic Assay for Long Chain Fattyacyl Peptides 
The longer chain fattyacyl peptides were dissolved in pure DMSO. The 
concentrations of peptides were determined at 280 nm using extinction coefficient of the 
two tryptophan residues attached at the C terminus of the peptides (since the tryptophan 
residues added to the peptides absorb predominantly at this wavelength). The final DMSO 
concentration in the reaction mixtures was maintained to be 2.5%. The peptide 
concentrations were varied from 1 to 20 µM. The reactions containing 2 mM NAD, 1 mM 
DTT, 20 mM Tris pH 8.0, 0.2 µM recombinant full length Sirt6, and acyl peptides at 
different concentrations were incubated for 15 min at 37 °C. The reactions were stopped 
using 1 volume of 0.5 N HCl in methanol. The reaction mixtures were spun at 18,000 g 
for 10 min and were analyzed using a Kinetex XB-C18 column (100 Å, 75 mm × 4.60 
mm, 2.6 μm, Phenomenex). The gradient of 0-55% B in 10 min at 0.5 ml//min was used. 
The product peak and the substrate peak were quantified using absorbance at 280 nm and 
converted to initial rates. Initial rates were then plotted against the acyl peptide 
concentration and fitted using the software KaleidaGraph. 
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3.3 Results 
The hydrophobic residues of Sirt6 enveloping the myristoyl backbone were mutated 
to the hydrophilic residue arginine. Our aim was to mutate the residues Leu9, Phe82, 
Phe86, and Val115 to find out whether these four mutants would have decreased 
defattyacylase activity. However, I could only obtain three of the mutants, L9R, F82R and 
V115R. Cloning was done using stratgene quickchange method (6) for the L9R mutant 
because the mutation was very close to the 5´ restriction site. V115R and F82R were 
cloned using the PCR overlap extension method. The details of the two cloning methods 
are described in the previous section. Fig. 3.1a - 3.1c show the purification of various 
Sirt6 mutant proteins in AE cells. The expected molecular weight of the proteins is 
approximately 39.9 kDa.   
 
 
Fig. 3.1a The purification of Sirt6 L9R mutant protein using Ni-NTA affinity 
purification. The Coomassie blue stained gel shows elutions obtained from Ni-NTA 
purification using different concentrations of imidazole solutions to obtain the Sirt6 L9R 
His6 –tagged protein. The protein was further subjected to cation exchange purification 
(not shown here). Lane key: Lane 1: Protein standard; 2: Cell lysate; 3: Supernatant; 4: 
Inclusion bodies; 5: Flow through; 6: 25 mM imidazole; 7: 100 mM imidazole –elution 1; 
8: 100 mM imidazole –elution 2; 9: 150 mM imidazole elution- 1; 10: 150 mM imidazole 
–elution 2; 11: 200 mM imidazole –elution 1; 12: 200 mM imidazole elution- 2. The 
eluted protein is show in the red box. 
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Fig. 3.1b The purification of Sirt6 F82R mutant protein using Ni-NTA affinity 
purification in the right panel. Left panel shows the fractions obtained from the cation 
exchange purification performed after the Ni-NTA purification. Right panel shows the 
Coomassie blue stained gel shows elutions obtained from Ni-NTA purification using 
different concentrations of imidazole solutions to obtain the Sirt6 F82R His6 –tagged 
protein. The protein was further subjected to cation exchange purification shown in the 
left panel. Right Panel Lane key: Lane 1: Protein standard; 2: Cell lysate; 3: Supernatant; 
4: Inclusion bodies; 5: Flow through; 6: 25 mM imidazole elution-1; 7: 25 mM imidazole 
elution-2 8: 100 mM imidazole elution- 1; 9: 100 mM imidazole elution-2; 10: 150 mM 
imidazole elution-1; 11: 150 mM imidazole –elution 2; 12: 200 mM imidazole elution-1; 
13: 200 mM imidazole elution-2. Left Panel shows the fractions obtained from cation 




Fig. 3.1c The purification of Sirt6 V115R mutant protein using Ni-NTA affinity 
purification. The Coomassie blue stained gel shows elutions obtained from Ni-NTA 
purification using different concentrations of imidazole solutions to obtain the Sirt6 
V115R His6 –tagged protein. Lane key: Lane 1: Protein standard; 2: Cell lysate; 3: 
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Supernatant; 4: Flow through; 5: 25 mM imidazole; 6: 100 mM imidazole –elution 1; 7: 
100 mM imidazole –elution 2; 8: 150 mM imidazole elution- 1; 9: 150 mM imidazole –
elution 2; 10: 200 mM imidazole –elution 1; 11: Protein standard. The 100 mM elution 
fractions were collected and further subjected to cation exchange purification (not 
shown). The eluted protein is show in the red box. 
 
 
Fig. 3.1d The purification of Sirt6 R65A mutant protein was performed using Ni-NTA 
affinity purification followed by the cation exchange purification. The Coomassie stained 
blue gel shows fractions obtained from the cation exchange purification. The fractions 6 
and 8 were collected; the expected weight of the proteins is 39.9 kDa. The eluted protein 




Fig. 3.1e The purification of Sirt6 H133Y mutant protein using Ni-NTA affinity 
purification (left) and cation exchange purification (right). The Coomassie blue stained 
gel on left shows elutions obtained from Ni-NTA purification using different 
concentrations of imidazole solutions to obtain the Sirt6 H133Y His6 –tagged protein. 
Lane key: Lane 1: Protein standard; 2: Cell lysate; 3: Supernatant; 4: Inclusion bodies; 5: 
Flow through; 6: 25 mM imidazole elution-1; 7: 100 mM imidazole elution- 1; 8: 100 
mM imidazole elution-2; 9: 150 mM imidazole elution-1; 10: 150 mM imidazole –elution 
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2; 11: 200 mM imidazole elution-1; 12: 200 mM imidazole elution-2. Right panel shows 
fractions obtained from the cation exchange purification. Fractions 7 and 8 were 




Fig. 3.1f The purification of Sirt6 G60A mutant protein using Ni-NTA affinity 
purification (left) and cation exchange purification (right). The Coomassie blue stained 
gel on left shows elutions obtained from Ni-NTA purification using different 
concentrations of imidazole solutions to obtain the Sirt6 G60A His6 –tagged protein. Lane 
key: Lane 1: Protein standard; 2: Cell lysate; 3: Supernatant; 4: Inclusion bodies; 5: Flow 
through; 6: 25 mM imidazole elution-1; 7: 25 mM imidazole elution-1; 8: 100 mM 
imidazole elution- 1; 9: 100 mM imidazole elution-2; 10: 150 mM imidazole elution-1; 
11: blank (some leaking from adjoining lane); 12: 150 mM imidazole elution-1; 13: 200 
mM imidazole elution-1. Right panel shows fractions obtained from the cation exchange 




Fig. 3.1g The purification of Sirt6 S56Y mutant protein using Ni-NTA affinity 
purification (left) and followed by the cation exchange purification (right). The 
Coomassie blue stained gel shows elutions obtained from Ni-NTA purification using 
different concentrations of imidazole solutions to obtain the Sirt6 S56Y His6 –tagged 
protein. The protein was further subjected to cation exchange purification (not shown 
here). Lane key: Lane 1: Protein standard; 2: Cell lysate; 3: Supernatant; 4: Inclusion 
bodies; 5: Flow through; 6: 25mM imidazole elution-1; 7: 25mM imidazole elution-2; 8: 
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100 mM imidazole –elution 1; 9: 100 mM imidazole –elution 2; 10: 150 mM imidazole 
elution- 1; 11: 150 mM imidazole –elution 2; 12: 200 mM imidazole –elution 1; 13: 200 
mM imidazole elution- 2. Right panel shows fractions obtained from the cation exchange 
purification. Fractions 7 and 8 were collected. The eluted protein is show in the red box. 
 
Fig. 3.1 The various Sirt6 mutant proteins purified in AE cells. The expected weight of 
the proteins is 39.9 kDa. 
 
HPLC based activity assays as described in the previous chapter need to be 
performed to assess the decaetylation and the defattyacylation activity of these mutants 
(namely L9R, F82R and V115R). Kinetic measurements for both deacetylation and 
defattyacylation will be helpful in identifying the inactive mutant for the novel 
defattyacylase activity.  
Another question we wanted to address was whether the mutants – G60A, R65A, 
H133Y, and S56Y, which have been well described in literature (2, 3), would have any 
effect on the novel defattyacylase activity. Towards this end, we cloned the above 
mentioned mutants using the PCR overlap extension method as described in Section 3.2. 
The proteins were expressed in the BL21R2 AE strain of the E. coli cells. Fig. 3.1d - 3.1g 
shows the purification for the mutant proteins.  
We then assessed the demyristoylation activity of these mutants using an HPLC 
based assay for obtaining the kinetic parameters. No demyristoylation was observed with 
the Ser6Tyr mutant. The G60A and H133Y mutants showed demyristoylation activity. A 
preliminary analysis of the kinetic parameters of the demyristoylation activity for the two 













. Considering these rough estimates, the demyristoylation activity of the 
two mutant proteins appears to be similar to Sirt6 WT demyristoylation activity. On the 
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other hand, the kcat/Km for the deacetylation activity of G60A, which is known to stop the 




. This is similar to the 
kcat/Km of deacetylation activity for Sirt6 WT. Further investigation is required to 
determine the kinetic parameter for the mutant R65A, which has been proposed in 
literature (2) to be responsible for abrogating the deacetylase activity (2, 3), especially in 
relation to the novel defattyacylase activity. However, more extensive study is needed to 
prove the relevance of these amino acids with respect to defattyacylase activity. 
It has also been reported in literature that Sirt6 ADP-ribosylates PARP-1 in 
response to the oxidative stress, thereby promoting the repair of DSBs (2, 3). Therefore, 
we were also interested in comparing how strong self ADP-ribosylation activity of Sirt6 
compared to the robust ADP-ribosylation of EF-2 by DT. Briefly, it was done by 
incubating the Sirt6 with 
32
P-NAD. The autoradiograph in Fig. 3.2 shows strong labeling 
for the DT catalyzed ADP-ribosylation of EF-2 compared to the self mono-ADP-
ribosylation of Sirt6. The comparison was done based on equal moles of substrates taken, 
i.e., Sirt6 and EF-2. 
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Fig. 3.2 Comparison of DT catalyzed ADP-ribosylation of EF-2 with self ADP-
ribosylation of Sirt6; left panel shows the autoradiograph of the 
32
P-NAD assay for the 
assessing ADP-ribosylation activity of Sirt6; right panel shows the commassie blue gel. 
Sirt6 protein is not visible on the gel due to low concentration (9 pmolar) 
 
3.4  Discussion 
        Our work in the previous chapter showed that Sirt6 is a more efficient defattyacylase 
than a deacetylase. Next, we wanted to explore the importance of some of the 
hydrophobic residues present in the acyl pocket of Sirt6. We also wanted to identify an 
inactive mutation which would abrogate the defattyacylase activity. We successfully 
cloned, expressed, and purified the mutant proteins. However, more experiments 
(specifically activity assay and kinetic assay) need to be done to confirm the inactive 
mutant and to study its effect on the TNFα secretion. 
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 Gorbunova et al. recently suggested that PARP-1 is ADP-ribosylated by Sirt6. The 
study pointed out some mutations such as G60A and R65A specifically abrogate the 
ADP-ribosyl transferase and the NAD-dependent deacetylase activities, respectively. We 
wanted to assess the efficiency of the ADP-ribosyltransferase activity of Sirt6 in 
comparison to the robust ADP-ribosyltransferase activity of other proteins (i.e. diptheria 
toxin catalyzed ADP-ribosylation on elongation factor-2). We also wanted to study how 
the mutants would affect the defattyacylase assay for Sirt6. We were partially able to 
determine the kinetic parameters for some of the mutants. Our kinetic study on the G60A 
mutant indicates that the mutation does not affect the defattyacylase activity. Our results 
also suggest that Sirt6 auto ADP-ribosylation might be weak when compared to the robust 
ADP-ribosylation of DT by EF-2.  More studies need to be performed to explore whether 
PARP-1 could be fattyacylated. It would also be interesting to investigate if the auto 
ADP-ribosyltransferase activity of Sirt6 would increase or decrease the defattyacylase 
activity. It is also possible that two activities might be independent and would act 
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CHAPTER 4 
Conclusion and Future Directions 
 
4.1 Introduction 
Sirtuins are NAD-dependent deacetylases. The aim of the present study was to 
look for an alternate and more efficient activity for one of the seven human sirtuins, Sirt6. 
Sirt6 has been important in various biological functions including the transcriptional 
regulation of genes involved in metabolism and inflammation (1, 2), genome stability (3) 
and lifespan expansion (4). All of these important biological functions are ascribed to the 
NAD-dependent deacetylase activity of Sirt6. However, the deacetylation activity of Sirt6 
is weak when compared to the deacetylation by other members of the sirtuin family, i.e. 
Sirt1, Sirt2, and Sirt3, which are known for the robust deacetylation of their substrates. 
The weak deacetylation activity of Sirt6 yet strong biological implications indicated a 
knowledge gap in the biochemistry of the protein. The main motivation for the present 
study comes from the work on Sirt5 (5), which suggests that although Sirt5 is a weak 
deacetylase, it possesses robust desuccinylase and demalonylase activities and that the 
protein malonylation is a new posttranslational modification. Hence, the aim of this study 
was to explore an alternate, more robust activity of Sirt6 by investigating whether Sirt6 
could hydrolyze any other physiologically relevant modifications on acyl lysine residue. 
We wanted to achieve this by studying various biochemical parameters such as kinetic 
parameters and reaction mechanism for the possible alternate activity.  
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4.2 Empirical Findings 
The approach followed in this work was to synthesize a small peptide library 
using the H3K9 histone peptide sequence as the backbone. Physiologically relevant acyl 
modifications were added to the lysine K9 side chain and an array of substrates was 
generated. These substrates were screened with the recombinant Sirt6 in order to check 
whether Sirt6 could reverse/remove these modifications using various biochemical 
techniques such as HPLC-MS, MALDI TOF spectroscopy, and biochemical 
radiolabeling. The synthesized peptide library was also useful later in screening other 
sirtuins of the same class but different species such as Pfsir2A for a novel activity (6). 
The major findings of this work include the following:  
a) Sirt6 exhibits a preference for removing longer chain fattyacyl modification from 
the H3K9 peptide backbone in comparison to other physiologically relevant 
modifications such as biotin, HMG, succinyl, lipoyl, acetyl, and ubiquitinyl. 




) is roughly 300 fold better than that 




). The increased catalytic efficiency comes mainly 
from the decrease in Km for the myristoyl peptide. The Km for deacetylation is 810 
µM and for demyristoylation it is 3.4 µM. 
c) The novel activity allows Sirt6 to utilize substrates other than the H3K9 acetyl 
peptide which is in contrast to its highly sequence specific deacetylation activity. 
d) The mechanism for the novel Sirt6 demyristoylase activity is the same as that for 
the deacetylase activity. 
e) O´-fattyacyl ADP-ribose intermediate was isolated using the HPLC based assay. 
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f) The crystal structure of Sirt6 with H3K9 myristoyl peptide and ADP-ribose was 
obtained, which demonstrated the presence of long hydrophobic acyl pocket 
preference of Sirt6 for long chain fattyacyl group. (This was a collaborative work 
done with Yi Wang and Professor Quan Hao.) 
g) The kinetic data using HPLC based assay shows that the demyristoylation of 
TNFα K19 and TNFα K20 myristoyl peptides by Sirt6 is robust. 
h) Sirt6 promotes the secretion of TNFα by removing the fattyacyl modification on 
Lys19 and Lys20 of TNFα. (This was a collaborative work Dr. Hoang Jiang.) 
 
4.3 Significance of This Work 
Sirt6 has been previously reported to be a very weak and sequence specific 
deacetylase. In this work, we have shown that Sirt6 shows low sequence specificity when 
the lysine residue has fattyacyl modification. Therefore, this novel Sirt6 activity supports 
the fact that different sirtuins might prefer different acyl lysine modifications (e.g., Sirt5 
prefers succinyl/malonyl modifications (5)) and that deacetylation might just be 
responsible partially for its function. It is a possibility that both deacetylation and 
defattyacylation activities might be present for Sirt6. Therefore, sirtuins should rather be 
broadly defined as “NAD-dependent deacylases” rather than just “NAD-dependent 
deacetylases.” Further, the discovery of defattyacylase activity of Sirt6 on protein lysine 
fattyacylation (here TNFα) gives us a new way to explore this previously less studied 
PTM (8, 9). Other signaling molecules such as insulin growth factor 1 (IGF-1) might be 
controlled by similar mechanism (3, 10). 
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4.4 Future Work 
Possible extensions of this work are as follows:  
a) The present study does not show which particular hydrophobic amino acid(s) in 
the catalytic pocket of Sirt6 is/are important for its “defattyacylase” activity. 
Testing an inactive mutation in enzymatic assays and further in TNFα secretion 
assays would further prove that the enzymatic activity is directly related to Sirt6 
and is not due to an interacting protein activation. 
b) Another extension could be to design inhibitors or activators which would 
specifically inhibit/activate the Sirt6 activity. Since different sirtuins prefer 
different acyl groups, specific inhibitors or activators could be synthesized for 
Sirt6. Using these inhibitors and activators, the physiological function of Sirt6 
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